Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chen-Lung Lin, MD
Pell Bio-Med Technology Co., Ltd.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Taiwan University Hospital
Taipei, Taiwan, Taiwan
Shang-Ju WuRecruiting - Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Yi-Chang LiuRecruiting - Chi Mei Medical Center
Tainan, Taiwan
Not, yet, recruiting - Taipei Medical University - Taipei Medical University Hospital
Taipei, Taiwan
Chao-Hua ChiuRecruiting - Taipei Veterans General Hospital
Taipei, Taiwan
Liang-Tsai HsiaoRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2022
- Primary completion
- 31 Dec 2026
- Completion
- 31 Mar 2027
- Last update posted
- 13 May 2025
- Registered enrollment
- 49
- Registry id
- NCT05326243
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.